ArticleEClinicalMedicine2024

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.

Teresa H Evering et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.